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Abstract
Chromodomain helicase DNA-binding (CHD) chromatin remodelers regulate transcription
and DNA repair. They govern cell-fate decisions during embryonic development and are
often deregulated in human pathologies. Chd1-8 show upon germline disruption pro-
nounced, often developmental lethal phenotypes. Here we show that contrary to Chd1-8 dis-
ruption, Chd9–/–animals are viable, fertile and display no developmental defects or disease
predisposition. Germline deletion of Chd9 only moderately affects gene expression in tis-
sues and derived cells, whereas acute depletion in human cancer cells elicits more robust
changes suggesting that CHD9 is a highly context-dependent chromatin regulator that, sur-
prisingly, is dispensable for mouse development.
Introduction
Normal organismal development requires accurate transcriptional control. This is achieved by
myriad of transcription factors and chromatin regulators that act in concert to control expres-
sion of the right genes at the right time. Chromodomain helicase DNA-binding enzymes
belong to the superfamily of chromatin remodelers that control nucleosomal structure and
phasing to regulate gene expression and DNA repair. They contain hallmark amino-terminal
double chromodomains and central SNF2 helicase-like ATPase domains, allowing nucleosome
recognition and remodeling [1]. Different accessory domains facilitate these actions [1]. The
CHD enzymes have limited DNA-specificity and rely on specific histone modifications and
transcription factors for recruitment to target loci [2]. Based on their constituent domains,
they are classified into three subfamilies: subfamily I (CHD1 and CHD2), subfamily II (CHD3,
CHD4 and CHD5) and subfamily III (CHD6, CHD7, CHD8 and CHD9).
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In addition to the hallmark domains, members of the subfamily III contain SANT–like and
tandem brahma kismet domains (BRK), implicated in DNA [3] and CTCF [4] binding, respec-
tively. These enzymes are homologs of Drosophila Kismet (KIS-L), a Trithorax family protein
that counteracts gene repression by Polycomb group proteins during development [5]. It regu-
lates early stages of RNA Polymerase II elongation [6] and is involved in key developmental
signaling pathways [7]. Importantly, kismet loss-of-function causes specific segmentation
defects and homeotic transformation [8] resulting in lethality. Most of these functions have
been conserved in the mammalian homologs.
Subfamily III members are found in both promoter and enhancer regions, regulating differ-
ent stages of RNA Polymerase I and II transcription [2,9]. Subfamily III members have limited
DNA affinity [10], and their recruitment to target loci is mediated through interaction with
methylated histone tails [9,11] and transcription factors [2]. Despite their high sequence similar-
ity, these enzymes display different substrate specificities and remodeling activities in vitro
[9,10].
CHD enzymes appear to have non-redundant functions in murine embryonic development
[12]. Chd7 knockout animals survive up to embryonic day 10.5 (E10.5) [13], whereas homozy-
gous deletion of Chd8 is embryonic lethal at E5.5–7.5 due to widespread p53-mediated apopto-
sis [14]. These enzymes act in a dose-dependent manner and mice heterozygous for Chd7 or
Chd8 faithfully recapitulate features of human CHARGE syndrome [15] and autism spectrum
disorders (ASD) [16], respectively.
Subfamily III enzymes are often deregulated or mutated in human cancers. In aggressive
breast cancers, CHD7 amplification and overexpression correlates with poor prognosis. In
contrast, heterozygous loss of CHD9 is observed in 55% of breast cancer patients [17]. Low
expression is also associated with poor prognosis in colorectal cancer [18]. In addition, a num-
ber of studies reported frequent mutations in human cancers: CHD6 in bladder cancer [19],
CHD7 in medulloblastoma [20,21], whereas CHD8 harbors mutations in many cancer types
[22].
CHD9 (also known as PRIC320 and CReMM) is the least characterized member of the sub-
family. It was identified as transcriptional regulator in rat liver [23] and mesenchymal stem
cells [24]. Biochemical studies revealed CHD9 interaction with H3K4me2/3, H3K9me2/3 and
H3K27me3 modified histones and illustrated its capacity to reposition nucleosomes in an
ATP-dependent manner [9].
CHD9 associates with nuclear receptors and contributes to glucocorticoid receptor–medi-
ated gene expression regulation [23,25] and might be involved in loosening the chromatin
structure in mouse oocytes [26]. Recent landmark study in mouse ES cells revealed that CHD9
chromatin occupancy correlates with gene expression levels and the presence of the H3K4me3
mark at a subset of loci [27].
While these studies address biochemical and functional properties of CHD9, the in vivo
functions of CHD9 have remained unresolved. Here, we describe the first Chd9 knockout
mice and study its contribution to development and lymphomagenesis, a tumor subtype in
which insertional mutagenesis experiments suggested a potential role of CHD9.
Results
CHD9 is dispensable for murine development and knockout does not
display overt phenotypic aberrations
Chd9 is ubiquitously expressed in murine tissues with the highest levels observed in brain [23].
Previous studies implicated CHD9 in stem cell biology [28], osteogenesis [29] and steroid-hor-
mone signaling [23,25], whereas insertional mutagenesis screens suggested an oncogenic
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driver role in murine [30,31] and human lymphomagenesis [32]. To explore the contribution
of CHD9 to development and tumorigenesis, we generated Chd9 knockout mice.
The vast majority of Chd family knockouts are embryonic lethal [12,33,34]. The reported
allele targeting strategies for Chd1-8 employed gene-trap reporter constructs, the deletion of
critical exons or the removal of functional domains ([12] and references therein). In the case
of Chd9 this was a particular challenge. Chd9, encoding a protein of 320 kD with a diversity of
functional domains (Fig 1A), contains several translation-initiation sites downstream from the
first ATG codon, raising the possibility of translation of shorter, truncated protein isoforms
that might exhibit dominant-active or dominant-negative functions. To circumvent this, we
deleted all protein coding exons of the locus by flanking the Chd9 open reading frame (ORF)
with two loxP sites by homologous recombination in mouse ES cells (ESC)(Fig 1A, S1 Fig).
Successful gene targeting of LoxP sites to the same Chd9 allele was confirmed by Southern blot
and PCR. The resulting Chd9 floxed mice (Chd9f/+) were crossed to the β-actin-driven Cre-
recombinase strain (ACTB-Cre) to obtain heterozygous Chd9 (Chd9+/–) animals (Fig 1A) and
backcrossed to FVB for two generations. Chd9+/–males and females were mated and offspring
characterized. Homozygous Chd9–/–animals were born at Mendelian ratio’s, appeared viable
and fertile with no immediate obvious defects (Fig 2A). The germline-deletion of Chd9 also
did not affect lifespan (log-rank test, p–value = 0.272; Fig 2A). This was striking, as all hitherto
published Chd family knockouts display severe phenotypes, ranging from embryonic lethality
[12,33,34] to male infertility [35].
Southern blot and PCR analysis of tissues and primary cells derived from wildtype, hetero-
zygous, and homozygous littermates showed complete deletion of the locus (Fig 1B). The Chd9
gene encodes two mRNA isoforms (Fig 1C and S6A Fig). Western blot and immunofluores-
cence staining confirmed depletion of the CHD9 protein in derived Chd9–/–ESCs and murine
embryonic fibroblasts (MEFs) (Fig 1C, S2 Fig). Deletion of the ORF resulted in a shorter
spliced mRNA species that corresponds to the remaining Chd9 exons that do not encode any
CHD9-specific protein domains (Fig 1C, S6A Fig).
Histopathology on small cohorts of matched littermates (3 months; wildtype (n = 5), homo-
zygous knockout (n = 5)) and older (12 months; wildtype (n = 6), homozygous knockout
(n = 6)) revealed no significant pathological changes, with mild inflammation in the liver,
lung, kidney and Harderian gland being the most distinctive (S1 Table). Wildtype, heterozy-
gous and homozygous littermates, that were aged and examined when moribund, displayed
only the phenotypic features characteristic for the strain background or old age. The majority
of these animals were older than 18 months when analyzed (Fig 2A). The most encountered
tumor types were adenocarcinomas/papillary carcinomas of the lung and some hepatomas,
adenomas of the Harderian gland, adenomas of the pituitary gland, adenocarcinomas of the
mammary gland, squamous cell carcinoma of the mucosal lining of the oral cavity and vagina,
and a few sarcomas such as histiocytic sarcoma, leiomyosarcoma and lymphoma (S1 Table).
The incidence and the type of the neoplasia were rather evenly distributed among the different
genotypes. Therefore, the pathologies found in the Chd9–/–mice were likely due to old age and
the strain genetic background. Collectively, the survival and histopathological analysis indicate
that Chd9 knockout animals are viable, fertile and display no overt phenotypes.
CHD9 depletion has a moderate effect on gene expression during murine
embryogenesis
Absence of overt phenotypes in Chd9–/–mice could be due to activation of compensatory tran-
scriptional programs or functional redundancy with other CHD enzymes. Additionally,
CHD9 might exert its functions during embryonic development rather than in adult tissues
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Fig 1. Generation of the Chd9 knockout results in complete removal of the locus coding potential. (A) (Above)
Representation of the CHD9 protein domains- CD (chromodomain), BRK (Brahma-Kismet domain), and (bellow) targeting
strategy whereby Cre–mediated deletion removed coding potential of the locus. (B) Left panel, Southern blot analysis of genomic
DNA from adult organs and ES cells from wild type and Chd9 knockout animals, using external and internal radioactive probes.
Right panel, PCR detection of deleted allele using primers 117kb apart. (C) Left panel, Northern blot mRNA detection in adult
brain and ES cells using 3’UTR and internal cDNA PCR–probes. Right panel, Western blot analysis showing complete depletion
of the CHD9 protein in ES cells. Vinculin used as a loading control.
https://doi.org/10.1371/journal.pone.0233394.g001
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with a concomitant greater potential for compensatory mechanisms to kick in. In adult mice
Chd9 is ubiquitously expressed, with the highest levels in brain (our data and [23]). During
murine embryogenesis, we observed high Chd9 mRNA levels at E13.5 and E15 (S8 Fig). High
expression was also observed in derived MEFs and ESCs (Fig 1C, S8 Fig). To explore the role
of CHD9 in gene expression regulation during development, we performed gene expression
analyses of knockout tissues (E15 liver and brain) and derived primary cells.
RNA–seq of Chd9 knockout embryonic (E15) liver and brain revealed only a handful of dif-
ferentially expressed genes (DEGs) (adjusted p–value� 0.05, log2FC� ±1) (Fig 2B, S3 Fig).
Importantly, Chd9 was the only downregulated mRNA in both tissues (Fig 2B, S3 Fig). More-
over, both liver and brain show concordant upregulation of an uncharacterized pseudogene
Gm4322 (Fig 2B, S3 Fig). Despite high Chd9 expression in the developing brain (S3B Fig), only
marginal upregulation of the Hoxa (a7), Hoxb (b6, b7, b9) and Hoxc (c5, c6) homeotic gene
clusters was observed (S3B Fig). Gene-set enrichment analysis (GSEA) of Chd9 knockout
brain revealed global downregulation of genes involved in complement and coagulation
Fig 2. Chd9 deletion does not affect murine survival and has moderate effect on gene expression. (A) Chd9 knockout
animals are viable, fertile and display no overt phenotypes. Kaplan–Meier survival curves reveal comparable life
expectancies of wild-type, heterozygous and homozygous knockout animals (ns = not significant, log-rank test p–
value = 0.272). (B) Venn diagram representation of the overlap between differentially expressed genes (DEGs) identified in
Chd9–/–MEFs, ESCs, E15 brain and liver. Numbers in parenthesis represent total number of DEGs between Chd9–/–and
Chd9+/+ cells and organs (p-adj< 0.05, log2FC (fold change)> ±1). The numbers in black indicate the number of non-
overlapping genes between analyzed groups.
https://doi.org/10.1371/journal.pone.0233394.g002
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cascades (KEGG: hsa04610), recently emerging as important regulators of the developing
brain [36] (S12 Fig). This might point to underlying transcriptional perturbations in embry-
onic brain in the absence of CHD9, albeit without overt phenotypic consequences. In the
knockout embryonic liver, GSEA showed upregulation of genes involved in Peroxisome func-
tioning (KEGG: hsa04146) (S12 Fig), in agreement with its previously identified role as peroxi-
some proliferator–activated receptor α (PPARα) interactor in liver [23].
RNA-seq analysis of knockout MEFs revealed only downregulation of Chd9 (Fig 2B) and
upregulation of the high mobility group protein B2 (Hmgb2) pseudogene Gm13237 (S4A Fig).
Pseudogenes might function as competitive endogenous RNAs (ceRNAs) regulating parent
gene expression [37]. However, Western blot analysis revealed no difference in protein levels
or isoform expression of HMGB2 and related HMGB1 proteins in Chd9–/–MEFs (S5 Fig).
Conversely, in derived Chd9–/–ESCs maintained in serum–free 2i media with leukemia
inhibitory factor (LIF), more profound gene expression changes were seen. In total, 63 upregu-
lated and 212 downregulated genes were observed (Fig 2B, S4B Fig). The GSEA revealed
downregulation of hedgehog signaling (HH) (KEGG: hsa04340) in knockout ESCs (S12 Fig),
implicating Chd9 as putative positive regulator of HH signaling. Notably, in D.melanogaster,
KIS-L is a transcriptional repressor of hedgehog signaling required for proper wing develop-
ment [7]. The absence of gene expression changes in Chd9–/–E15 tissues and MEFs appears
not to be due to compensatory transcriptional deregulation of other CHD enzymes or Poly-
comb repressive complex 1 and 2 proteins (PRC1 and PRC2) (S3 and S4 Figs).
Chd9 knockout mice display a mild expansion of the short-term
hematopoietic stem cell compartment
Of the CHD subfamily III, CHD7 regulates developmental hematopoiesis [38] and expansion
of hematopoietic stem and progenitor cells, whereas CHD8 is required for survival of both
non-transformed pre-B cells and acute lymphoblastic B-cell leukemia cells as well as EμMyc B-
cell lymphomas [39]. In view of the role of these subfamily III CHDs in normal and malignant
hematopoiesis, we asked whether Chd9 germline deletion might perturb hematopoiesis.
Flow cytometric analysis (FACS) of bone marrow (BM) of Chd9–/–mice showed a reduction
in the lineage-negative (Lin-) adult hematopoietic stem and progenitor cell population
(HSPCs), although this was not statistically significant (p-value = 0.055), (Fig 3A). We also
observed a tendency for a reduced frequency of the hematopoietic stem cells (HSCs, p–
value = 0.53) and multipotent progenitors (MPPs, p–value = 0.78). Notably, Chd9–/–animals
displayed a reduced frequency of the long-term hematopoietic stem cells (LT-HSC, p–
value = 0.06) and statistically significant expansion of short-term hematopoietic stem cell
(ST-HSC, p–value = 0.02) (Fig 3A). Depletion of CHD9 might affect cell–intrinsic programs
(transcriptional or metabolic) or interaction with local stem cell niches, impeding self–renewal
of LT-HSCs. In turn, this may lead to a compensatory increase of the ST-HSCs compartment,
thereby maintaining hematopoietic homeostasis [40]. However, there was no significant effect
on frequency and number of bone marrow multipotent progenitors (MPPs), common lym-
phoid (CLP) and common myeloid progenitors (CMP), and their more differentiated progeni-
tors (Fig 3B). Likewise, Chd9–/–and control animals displayed comparable frequencies of
thymic and splenic lymphoid cells (S6A and S6B Fig), as well as mononuclear leukocytes (lym-
phocytes, monocytes and macrophages) and granulocytes (eosinophils and neutrophils) in
peripheral blood (S6C Fig). Taken together, FACS analysis revealed that Chd9–/–mice display a
modest expansion of ST–HSC in bone marrow, with no discernible effects on lineage–
restricted progenitors and white blood cells.
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CHD9 does not contribute to EμMyc -driven lymphomagenesis or
transformation of MEFs
Several studies point to a role of CHD subfamily III members as drivers of hematopoietic can-
cers. CHD8 is required for survival of pre-B cells, acute lymphoblastic B-cell leukemia cells,
and EμMyc B-cell lymphomas [39]. Interestingly, insertional mutagenesis screens, performed
by us and others, identified the Chd9 locus as common integration sites in murine [30,31] and
human lymphomagenesis [32]. Moreover, downregulation of CHD9 expression is reported in
multiple myeloma [41] and diffuse large B–cell (DLBCL) lymphoma patients [42]. To more
rigorously document a potential role of CHD9 in lymphomagenesis, we crossed the Chd9–/
–strain with EμMyc transgenic mice hypothesizing that if CHD9 would have an oncogenic or
tumor-suppressing activity this should be revealed through an acceleration or delay of tumori-
genesis, respectively. However, EμMyc-driven lymphomagenesis was not affected by the Chd9
status (ns = not significant, log-rank test, p–value = 0.78) (Fig 4A) and the observed lesions
showed the typical marker profile well known from EμMyc mice (S7B Fig).
In order to assess whether CHD9 showed an effect on lymphoma gene expression, we pro-
filed lymphomas from EμMyc Chd9 wildtype, heterozygous and knockout mice by RNA-seq.
In the heterozygous tumours, 20 genes were upregulated and only leucine rich repeat neuro-
nal 4 (Lrnn4) downregulation was observed, whereas in the knockout tumours 28 genes
were up–and 8 down–regulated (S7C Fig). The presence of a shared subset of upregulated
Fig 3. Chd9 knockout animals display mild effect on hematopoietic stem cells. (A,B) Flow cytometric analysis of Chd9 wild-
type (WT, n = 3) and knockout (KO, n = 4) bone marrow (BM) stem cell and progenitor cells revealed expansion of short–term
hematopoietic stem cells (red asterisk denotes p–value: 0.018, ST–HSC). Other BM hematopoietic stem cell and progenitor
populations display no statistically significant differences. Data plotted as frequency of hematopoietic cells, mean ±SD, p-value
calculated using two-tailed Student’s t–test. HSCP- hematopoietic stem cells and progenitors: Lin−(lineage negative), HSC
(hematopoietic stem cells), MPP (multipotent progenitor cells), LT-HSC (long-term hematopoietic stem cells). Progenitors: IgM+
(B-cell progenitors), CMP (common myeloid precursor), GMP (granulocyte-monocyte progenitors), MEP (megakaryocyte-
erythroid progenitors).
https://doi.org/10.1371/journal.pone.0233394.g003
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genes in both CHD9 heterozygous and knockout lymphomas suggests that they might be
direct target genes (Fig 4B, S7C Fig) whereas the modest changes in gene expression observed
between tumors likely reflect variability in collaborating lesions elicited during tumor
development.
Since Chd9 is highly expressed in MEFs, we also examined its requirement for cell prolifera-
tion and transformation. Chd9 deletion did not affect proliferation under normal culture con-
ditions, or anchorage-independent growth of RasV12/Myc–or RasV12/E1a–transformed
MEFs (S9 Fig).
These results indicate that Chd9 deletion does not affect latency or histopathological fea-
tures of EμMyc-driven lymphomagenesis nor does it modulate the oncogenic transformation
of MEFs.
CHD9 depletion deregulates gene expression in human cancer cell lines
Lastly, we explored gene expression regulation by CHD9 in human cancer cell lines. Publicly
available data sets indicate that CHD9 is overexpressed in cancers of neuronal and hematopoi-
etic origin (S10 Fig). Analysis of a panel of human cancer cell lines revealed high CHD9 pro-
tein levels in SNB19 glioblastoma and K562 chronic myelogenous leukemia cell lines (Fig 5A
and 5B, S8 Fig). To address the role of CHD9 in gene expression regulation in these human
cancer cell lines, we generated SNB19 and K562 cell lines bearing doxycycline-inducible short
hairpin RNAs (shRNA) targeting CHD9 and confirmed successful depletion of the protein
upon knockdown induction by Western blotting (Fig 5A and 5B). Contrary to observations in
Chd9–/–mouse models, RNA-seq analysis in these cell lines revealed profound gene expression
changes 48 hours upon CHD9 depletion (Fig 5C and 5D, S11 Fig). In K562 cells, CHD9 knock-
down resulted in 215 down- and 635 upregulated genes, whereas in SNB19 cells, 121 down-
and 113 up–regulated genes were observed (S11 Fig). The GSEA revealed global downregula-
tion of genes involved in oxidative phosphorylation (KEGG: hsa00190) in K562 cells, whereas
in SNB19 the analysis showed downregulation of genes involved in cerebellar long-term
depression (KEGG: hsa04730), considered a molecular basis for cerebellar learning (S12 Fig).
Fig 4. Chd9 deletion does not affect latency or gene expression of EμMyc–driven lymphomagenesis. (A) Kaplan–Meier plot
shows comparable tumor-free survival of EμMyc;Chd9 animals (ns = not significant, log-rank test, p–value = 0.78). (B) Venn
diagram representation of the overlap between differentially expressed genes (DEGs) identified in EμMyc;Chd9+/–(left) and
EμMyc;Chd9–/–(right) compared to control EμMyc;Chd9+/+ lymphomas. Numbers in parenthesis represent total number of
DEGs (p-adj< 0.05, log2FC (fold change)> ±1). The DEGs common for EμMyc;Chd9+/–and EμMyc;Chd9+/+ samples are
highlighted in black and non-overlapping genes in red.
https://doi.org/10.1371/journal.pone.0233394.g004
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Notably, a number of deregulated genes in CHD9-depleted K562 cells–such as PBX Homeo-
box1 (PBX1), Apelin receptor (APLNR) and Bridging Integrator 1 (BIN1)–are implicated in
neuronal development and pathology [43]. This suggests a more widespread role for CHD9 in
regulation of neuronal-specific genes, which even shows up in the context of malignant
hematopoietic K562 cells. We did not find significant overlap in DEGs between both human
cancer cell lines. This was not unexpected, as K562 and SNB19 cells represent different lineages
and CHD9 may exert context–dependent roles as a repressor or activator of gene expression.
Interestingly, despite robust changes in gene expression, we did not observe differences in pro-
liferation upon depletion of CHD9 in these cells (S11 Fig) in line with recent genome-wide
CRISPR-Cas9 drop-out screens that failed to identify essential roles for CHD9 in a compre-
hensive panel of human cancer cell lines [44].
Discussion
Our results reveal that, despite ubiquitous expression, Chd9 is dispensable for embryonic
development. Furthermore, knockout animals are viable, fertile, display no overt phenotypes
Fig 5. CHD9 depletion deregulates gene expression in human SNB19 and K562 cancer cells. (A, B) Western blots reveal
depletion of the CHD9 protein by RNA-interference 48-hrs post doxycycline addition (±DOX). (C, D) Heatmaps of the top 20
most significant DEGs based on the p-adj value in SNB19 and K562 cells upon CHD9 knockdown. The color scale is based on the
normalized read count values.
https://doi.org/10.1371/journal.pone.0233394.g005
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and have a normal lifespan. We have only observed modest expansion of ST-HSC in bone
marrow, however, without discernible effect on other progenitors and mature populations.
Moreover, although several murine and human studies suggested a role for Chd9 in solid
tumors and lymphomas, CHD9 depletion did neither accelerate nor impair EμMyc-driven
lymphomagenesis. Likewise, CHD9 is not required for proliferation or oncogenic transforma-
tion of primary MEFs. Nevertheless, a complex protein of 320 kD with multiple functional
domains and highly conserved in evolution should have an important role. The lack of pheno-
type we noted is especially remarkable given the pronounced phenotype of nearly all other
CHD proteins. However, if the role of CHD9 has evolved during evolution for specific neuro-
nal functions, that are not required or do not become apparent in the routine monitoring tak-
ing place in dedicated mouse facilities, it might be not too surprising that our analyses did not
reveal such functions. Future detailed studies will be required to elucidate this.
Materials and methods
Animal study design and ethics statement
The study was performed in accordance with the Dutch and European regulations on care and
protection of laboratory animals. All animal experiments were approved by the local Animal
Ethics Committee—Dierexperimentencommissie (DEC) of The Netherlands Cancer Institute
(NKI)- (OZP ID: 05029). All animal strains used in this study were generated or obtained
through The Netherlands Cancer Institute Animal Facility. The number of animals required
for each of the analyses performed in this paper are indicated either in the main text, figure
panels or figure legends. The comparison of survival curves between experimental animal
cohorts is done using log-rank (Mantel-Cox) test using GraphPad Prism8. For all calculations
of p-values, significance threshold alpha was set at 5% (p< 0.05).
Since no previous knowledge on CHD9 role in murine development/lifespan is available,
duration of the experiment was set for the maximum period of three years as to be able to
show an effect on longevity in case this would be influenced by CHD9. Previous studies show
that EμMyc mice succumb to lymphomas at average of 5 months. EμMyc;Chd9 mice were
monitored for the maximum period of two years, as it was not known whether Chd9 loss
would accelerate or decelerate tumorigenesis.
Animals were kept in standard husbandry conditions (open-cages, standard condition of
bedding and enrichment, feeding, light, and temperature, with free access to food and water).
Animals were monitored daily by trained animal technicians at the NKI Animal Facility. Any
symptoms of disease or poor health (weight loss, abnormal sedentary behaviour, difficulty
breathing, uncoordinated or impaired movement) were considered grounds for euthanasia.
Moribund animals were promptly euthanised with CO2, confirmed by lack of response to firm
toe pinch, and necropsy was performed to identify macroscopic changes and, when deemed
needed, tissue samples were processed for immunohistopathology to document microscopic
abnormalities. No animals died prior to meeting the criteria for euthanasia. No anaesthesia,
analgesia or special techniques were required or applied during the experiments.
Generation of the Chd9 conditional knockout mouse strain
The endogenous Chd9 locus on chromosome 8 was flanked by loxP sites on both sites of the
gene in order to excise the whole coding potential of the locus upon Cre-mediated recombina-
tion. The 5’ loxP site was introduced upstream of the exon 3 (containing ATG translation initi-
ation site), whereas at the 3’ end a second loxP site was introduced downstream of the exon 38.
Targeting was performed in E14 ES IB10 cells of 129P2 genotype using the recombineering-
based method for generating conditional knockout mutations [45]. Since ES cells were
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targeted at two sites 117 kb apart, the original method had to be adapted for two-step targeting
strategy.
Construction of retrieval and targeting vectors. Primer sequences used for constructing
the Chd9 conditional knockout vector are listed below:
5’ primer A NotI-Chd9 5’ ATAAGCGGCCGCGTGAAAGCAAGCGGCTTA
5’ primer B HIII-Chd9 5’ GTCAAGCTTCTGGGTGTGGTGATGTACG
5’ primer Y HIII-Chd9 5’ GTCAAGCTTGCGGTGTTATAGAATATGAGCG
5’ primer Z SpeI-Chd9 5’ TCTACTAGTGAATCACTTGGAAACACTCG
5’ primer C NotI-Chd9 5’ ATAAGCGGCCGCCACAGAGAAACCCTGTCTGA
5’ primer D RI/BglII-Chd9 5’ GTCGAATTCAGATCTCAAGCATCTTCCTATAGTCAG
5’ primer E BamHIII-Chd9 5’ ATAGGATCCCATTCGCTTCACAGATACCT
5’ primer F SalI-Chd9 5’ CGCGTCGACGTCGCGGTAGGTTATTACGGTATCA
3’ primer A NotI-Chd9 5’ ATAAGCGGCCGCATGAACTGATCCTCGGTTACA
3’ primer B HIII-Chd9 5’ GTCAAGCTTACGCCAAATGGAGTATACG
3’ primer Y HIII-Chd9 5’ GTCAAGCTTGAAAGGCTATCCCAGTACGT
3’ primer Z SpeI-Chd9 5’ TCTACTAGTACACCAAGACCAACATCATCCG
3’ primer C NotI-Chd9 5’ ATAAGCGGCCGCTCCCTGTCTTGCCTCCTATG
3’ primer D RI/BglII-Chd9 5’ GTCGAATTCAGATCTATTGCTAATTAACGTAGATGTCG
3’ primer E BamHI-Chd9 5’ ATAGGATCCCAAGACGGTCCTTCCATGG
3’ primer F SalI-Chd9 5’ CGCGTCGACGTCCAATCTGCAACAATATGCGTA
The 5’ arm was retrieved from EL350 cells from BAC RP23-296 (RPCI-BAC library, de
Jong lab) [46]. The 3’ arm was retrieved from EL350 cells from BAC bMQ-244 (129 S7 Gene-
service, Cambridge, UK).
The retrieval vector was generated by mixing 3 μL of PCR product 1 (left arm AB, NotI/
HindIII), 3 μL of PCR product 2 (right arm YZ, HindIII/SpeI), 2 μL of MC1TK(PL253, NotI/
SpeI), 1 μL of 10× ligation buffer, and 1 μL of T4 DNA ligase.
The Neo-targeting vector were generated by mixing 3 μL of PCR product 1 (left arm, NotI/
EcoRI, CD), 3 μL of PCR product 2 (right arm, BamHI/SalI, EF), 2 μL of floxed Neo cassette
(PL452 or PL451,EcoRI/BamHI), 1 μL of the retieved Bac DNA fragment NotI/SalI), 1.2 μL of
10× ligation buffer, and 1 μL of T4 DNA ligase.
Gene targeting in mouse ES cells. First targeting. For gene targeting, 25 μg of NotI-linear-
ized 5’ Chd9 cko-targeting vector DNA was electroporated into 10 × 106 ES cells E14 IB10
(129P2 genotype) were grown on feeder MEFs. Transfectants were selected in CM medium
(10% fetal calf serum in GMEM with 2 mM L-glutamine) with G418 (200 μg/ml). Correctly
targeted clones were identified by Southern blot analysis of a HindIII digest genomic DNA
with the 50 probe (primers F22- 5’ATTTGTGCGCATGAACTGC; R431-5’ GTCGAGCAG-
TAAGGCTAAAGTAA). Correctly 5’ targeted clone was electroporated with the PGK-Cre/
PGK-Puro plasmid in order to excise the loxP floxed neo cassette. Clones with excised neo cas-
sette were identified by PCR analysis using primers FRW- 5’TCTCAGAGGCTGGTGTTT
GTTTC; REV- 5’CACAAGAAGGTGACCCAGAA.
Second targeting. The selected 5’ targeted clone was electroporated with 25 μg NotI-linear-
ized 3’ Chd9 cko-targeting vector DNA with a Frt floxed neo cassette and a loxP sequence in
the same orientation as the loxP sequence at the 5’ side of the Chd9 gene. Correctly targeted
clones were identified by Southern blot analysis of a HindIII digest with the 30 probe (exon 39
primers FRW- 5’TGTTTGTTTGCTTACAGGTTGG; REV- 5’ TCTAAGGCAGAAT
CAAATGGTTT).
Cis targeted clones. In order to detect targeted ES clones with both 5’ and 3’ loxP sequences
on the same chromosome (cis targeting), double mutant ES cell clones were electroporated for
transient Cre expression by PGK-Cre/PGK-Puro plasmid. Excision of the Chd9 protein-
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coding exons 3–38 was demonstrated by PCR using primers (Δ-PCR): FRW-5’ CCCGAGTG
TGGGTTTAAATG; REV-5’ CCAATCTAACTGGGCTACCG.
Generation of conditional Chd9 knockout mice. Correctly targeted neomycine-resistant
ES clones harbouring two loxP sequences on the same chromosome flanking the Chd9 gene,
were injected into C57BL/6 blastocysts, and chimeras were crossed with FVB/N mice to pro-
duce heterozygous offspring. The resulting Chd9 f/+ heterozygous and subsequent Chd9 f/+
homozygous mice were viable and fertile and showed a normal lifespan, indicating that the
Chd9 f/+ conditional allele is fully functional.
Excision of the Frt floxed neo cassette. The neo cassette at the 3’ end of the Chd9 gene
was excised by crossing the mice with the Flpe deleter strain (FVB background).
Generation of heterozygous Chd9 knockout mice. To generate heterozygous knockout
allele, Chd9 f/+ mice were crossed with Acre germline deleter strain (Beta-actin driven expres-
sion of Cre recombinase). Mice were backcrossed to FVB background for two generations and
Chd9+/- males and females were bred to generate experimental cohorts.
Generation of EμMyc; Chd9 strain. Chd9-/- males were crossed with females bearing
EμMyc transgene [47] (maintained on FVB/NCrl background) to obtain Chd9+/-; EμMyc ani-
mals, which were subsequently crossed with Chd9+/- animals to generate experimental cohorts
(1/8 Chd9 wildtype and homozygous, and 1/4 Chd9 heterozygous animals bearing EμMyc
transgene).
DNA isolation and Southern blotting
DNA was isolated from tails and organs using DirectPCR Lysis Reagent (Viagen Biotech). For
Southern blot 10 μg of DNA was digested with 4 μL HindIII (Roche) in reaction containing
7 μL buffer B (NEB), 1.4 μL spermidine (Sigma Aldrich) and 0.7 μL BSA(Sigma) in 70 μL vol-
ume. DNA was resolved on 0.8% agarose gel at 30V overnight and transferred to Amersham
Hybond N+ membrane (GE Healthcare) in SSC (Sigma). Probes were PCR amplified from
genomic DNA in a reaction mix with 32P-dCTP (Perkin Elmer) using primers: (External
probe) FRW: ATTTGTGCGCATGAACTGC, REV: GTCGAGCAGTAAGGCTAAAGTAA and
(Internal probe) FRW: TGTGCATCTCCACTTTGAGC, REV: CATTAATGCATGGCCAGTTG.
RNA isolation and Northern blotting
Northern blot was performed using standard protocol. Briefly, RNA was isolated from frozen
tissues, tumour pieces and cell pellets using TRIzol reagent (Ambion) and RNEasy columns
(Qiagen). 10 μg of total RNA was resolved on agarose/formamide gel at 20mV for 6hrs; trans-
ferred to Amersham Hybond N+ membrane (GE Healthcare) in 20xSSC (Sigma), baked for
1.5hrs at 80˚C and UV–crosslinked. Probe was PCR amplified from cDNA template in reac-
tion mix with 32P-dCTP (Perkin Elmer) using primers: Internal-FRW: 5’ CAGACGAGGGTT-
CAGAGAGG, Internal-REV: 5’ TTCTTCCAGAAAGTATGTTTGAACG; and 3’ UTR- FRW:
5’CAGACGAGGGTTCAGAGAGG, 3’UTR-REV: 5’ACATCGAGTTCAGAAACGTATGG. Prehybri-
dization (1hr) and hybridization (o/n) with the probe was done at 65˚C in Church buffer.
Membrane was washed consecutively in 2xSSC, 2xSSC 0.1%SDS, 0.5xSSC 0.1%SDS buffers,
exposed on phosphor screen, and image was acquired on phosphorimager.
Protein isolation and Western blotting
Western blot was performed using standard protocol. Briefly, cells were trypsinized, pelleted,
washed in ice-cold PBS, lysed in RIPA buffer on ice, briefly sonicated and cleared by centrifu-
gation. Protein was resolved on 3–8% gradient Tris-Acetate precast NuPAGE gels (Invitrogen)
and transferred onto 0.45 μm Immobilon-P PVDF membrane (Merck Millipore) in 2x Tris-
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Glycine transfer buffer supplemented with 0.01% SDS for 16hrs at 100mA at 4˚C. Membrane
was blocked for 4hrs in 5% skimmed milk in TBST at 4˚C. Rabbit anti-CHD9 antibody (Bethyl
Laboratories, A301-226A) or mouse anti-Vinculin (V9131, Sigma) was incubated in blocking
buffer at 1:1000 dilution o/n at 4˚C. After three washes with TBST, antibody was incubated
with 1:10.000 dilution of secondary goat anti-rabbit antibody coupled to horseradish peroxi-
dase for 1hr at ambient temperature, followed by three washes in TBST. Immuno-complexes
were visualised by incubation in Pierce enhanced chemiluminescent (ECL) blotting substrate
(Thermofisher).
Immunofluorescence and immunohistochemistry
MEFs were plated in 8-well glass slide chamber system (Labtek), washed in PBS, fixed in PBS/
3.7% formaldehyde (Merck), permeabilised with PBS/ 0.1% Triton X-100 (Sigma) and blocked
in 10%FBS/PBS. The rabbit anti-CHD9 antibody (Bethyl Laboratories, A301-226A) at dilution
1:1000 was incubated o/n at 4˚C, followed by goat anti-rabbit secondary antibody conjugated
to Alexa Fluor 488 (1:500); chromatin was counterstained with DAPI (Thermo Scientific), and
mounted with Vectashield (Bioconnect). Images were acquired on Leica SP5 Scanning Confo-
cal Microscope.
Tissues were fixed in either 4% formaline or acidified formaldehyde (ethanol/acetic acid/
formaldehyde/saline at 40:5:10:45 v/v). Haematoxylin and eosin (H&E) stainings and immuno-
histochemical procedures were performed according to standard procedures. Sections were
prepared at 2 μm thickness from the paraffin blocks and stained with hematoxylin and eosin
(HE) according to standard procedures. For immunohistochemistry (IHC), 4 μm -thick sec-
tions were made. Primary antibodies were obtained from the following sources: B220 (NKI,
1:4000), Pax5 (Genetex, GTX63400, 1:250), CD3 (Neomarkers, RM-9107-S, 1:600), Myeloper-
oxidase (DakoCytomation, A0398, 1:600), F4/80 (Serotec, MCA497A, 1:200). Antibody staining
was revealed using either diaminobenzidine or 3-amino-9-ethylcarbazole chromogen. Images
were captured using a Zeiss Axioskop2 Plus microscope (Carl Zeiss equipped with a Zeiss Axio-
Cam HRc digital camera) and processed using AxioVision 4 software (Carl Zeiss Vision).
Derivation of MEFs and ES cells
Mouse embryonic fibroblasts (MEFs) were isolated from the Chd9+/- x Chd9+/- cross at day
13.5 post coitum and cultured using standard methods. Briefly, heads and organs of embryonic
day 13.5 embryos were removed, and the remaining fetal tissue was minced, rinsed in PBS,
and incubated for 1 hr in 0.5 ml of 0.1% trypsin/EDTA solution at 37˚C. Subsequently, the cell
aggregates were dissociated in DMEM supplemented with 10% FBS (GIBCO) and 1% penicil-
lin-streptomycin (GIBCO). After removal of large clumps, the cells were plated in a 175-cm2
flask. After 2–3 days, confluent cultures were frozen down and considered as being passage 1.
Embryonic stem cells (ESC) were derived and cultured from the Chd9+/- x Chd9+/- cross as
described before [48]. ESCs were cultured on 0.1% gelatin-coated plates in N2B27 medium
(DMEM/F12 from Gibco, Neurobasal medium, N2 supplement and B27 supplement from
Invitrogen) with LIF (Chemicon) and 2i, i.e. 1 μM PD0325901 (Axon Medchem) and 3 μM
CHIR99021 (Axon MedChem). ESCs were split between 1:4 and 1:8 every 2–3 days and disso-
ciated with Accutase (Sigma). Cells were cultured at 37˚C in 5% CO2. For all the experiments
early passage MEFs and ESCs were used.
Cell culture conditions
Cells were grown at 37˚C, 5% CO2, either in DMEM (GIBCO) supplemented with 10% FCS,
100 units per ml penicillin, 100 mg/ml streptomycin or in RPMI- 1640 (GIBCO)
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supplemented with 10% FCS, 100 units per ml penicillin, 100 mg/ml streptomycin. K562 and
SNB19 cells were available within The Netherlands Cancer Institute, originally purchased
from American Type Culture Collection (ATCC), and confirmed to be mycoplasma free.
SNB19 cells were cultured in DMEM (Invitrogen) and K562 in RPMI-1640 (Invitrogen)
media supplemented with 10% FBS and Pen/Strep (Gibco). For doxycycline induction of
pLKO-tet-shRNA constructs, cells were grown in same media supplemented with 10% Tet sys-
tem approved FBS (Clontech) and 100 units per ml penicillin, 100 mg/ml streptomycin.
Knockdown was induced by adding 1 μg/ml doxycycline (Sigma). 48 hours upon knockdown
cells were pelleted for RNA/protein isolation or plated for proliferation assay. The shRNA
sequences used in this study are: shRNA-Luciferase: CGCTGAGTACTTCGAAATGTC, shRNA
-CHD9#1: TGCATACCAGCGTACTAATAA, shRNA-CHD9#2: CCGAGCTCTCTTAGCATATTG.
Proliferation and transformation assays. For proliferation assay, 25.000 MEFs were
seeded in a 12-well plate, fixed in 4% PFA and stained with Crystal Violet (Merck) Ethanol
solution for 10 min at RT at indicated time points. Stained cells were dissolved in 10% acetic
acid, diluted 1:4 in MQ and absorbance was measured at OD590nm. Experiment was per-
formed twice, with two knockout and wildtype MEFs seeded in triplicate. Values represent
average ± SEM, two-way ANOVA was used to determine statistical significance.
Proliferation assay of human SNB19 glioblastoma cells with inducible pLKO-tet-
shRNA-CHD9 was done using the same protocol, with only difference that prior to seeding
cells were treated with 1μg/ml doxycycline (Sigma) for 48hrs. Cells were fixed and processed at
indicated time points as described above. Doxycycline was kept for duration of the whole
experiment.
Proliferation assay of human K562 cells was done as described above, with one major differ-
ence that cells were plated in a 6-well in triplicate and cell number was assayed daily using
CASY Cell counter without replating. Doxycycline was kept for duration of the whole experi-
ment. Values represent average ± SEM, two-way ANOVA was used to determine statistical
significance.
For soft agar growth analysis, MEFs were first infected with LZRS-TBX2-GFP, followed by
infection with Myc, RasV12 and E1A or combinations thereof. Oncogene expression following
transduction was confirmed on the Western blot. After selection, 50,000 MEFs were resus-
pended in 0.4% soft agar and plated on a bottom layer of 1% agar per well of a 6-well ultra-low
attachment plate (Corning) in triplicate. The number of colonies growing in soft agar after two
weeks of culture was quantified using ImageJ software. Experiment was performed twice,
using two wildtype and knockout MEFs, data values are represented as average ± SEM, p-
value calculated using two-tailed Student’s t-test.
All statistical analyses of cell proliferation and transformation was done using GraphPad
Prism8. For all calculations of p-values, significance threshold alpha was set at 5% (p< 0.05).
FACS analysis of hematopoietic lineages
Hematology. Peripheral blood was collected into EDTA-coated microtubes and analyzed
by FACS. Blood was depleted from red blood cells by hypotonic lysis and staining was per-
formed with fluorochrome-labelled antibodies specific for B220, CD3, CD11b. Samples were
analyzed on the LSR Fortessa cell analyzer (BD).
Flow cytometric analyses of hematopoietic subpopulations. Flow cytometric analysis
was performed as described previously [49]. BM mononuclear cells (MNCs) were stained for
lymphoid and myeloid lineage markers. To analyze and isolate BM LSK, LT-HSC, ST-HSC,
MPP, CLP, and CMP subpopulations, MNCs were first stained with Lineage Cell Detection
Cocktail-Biotinylated mouse antibody (Macs; Miltenyi Biotec). For FACS analysis, cells were
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then directly stained with fluorochrome-conjugated antibodies against Sca1 (Pacific blue), c-
kit (APC), CD34 (FITC), CD135/Flk2 (PE), CD150 (PECy7), CD16/32 (PerCpCy5,5), and
CD127 (PerCpCy5,5). For cell sorting of LSK, LT-HSC, and ST-HSC, depletion of lineage pos-
itive cells was performed using Biotin MicroBeads (Macs; Miltenyi Biotec) and magnetic col-
umns (Macs; Miltenyi Biotec) before staining. Samples were analyzed with CyAn ADP
Analyzer. Cell sorting was performed with a FACSAria cell analyzer (BD). All FACS data were
analyzed using FlowJo Software (Tree Star). For all FACS analysis p-value was calculated using
two-tailed Student’s t-test in Microsoft Excel. For all calculations of p-values, significance
threshold alpha was set at 5% (p< 0.05).
Antibody list. Blood lymphoid. CD4-Fitc (BioLegend), CD8-PE-Cy7 (BD), B220–Pacific
blue (BD), CD11b-PerCpCy5,5 (BD), CD3-APC (BioLegend); Blood myeloid and erythroid:
CD3-Fitc (BD), CD19-Fitc (BD), B220-Fitc (BD), Gr1-PE (BD), F4/80-Pacific blue (BioLe-
gend), CD11b-APC (BD);
BM lymphoid. IgD-Fitc (BD), CD25-PE (BioLegend), CD11b-PerCpCy5,5 (BD),
IgM-PECy7 (Southern Biotech), B220-Pacific blue (BD), cKit-APC (BD); BMmyeloid: Gr1-PE
(BD), CD11b-PerCpCy5,5 (BD), Ter119-PECy7 (BD), F4/80–Pacific blue (BioLegend),
CD19-APC (BioLegend); BMmegakaryocyte: CD3-Fitc (BD), CD41-PE (BioLegend), CD11b-
PerCpCy5,5 (BD), B220–Pacific blue (BD), CD19-APC (BioLegend); HSPC and CLP: Strep-
APC/CY7 (Southern Biotech), cKit-APC (BD), SCA1-PacBlue (BioLegend), CD34-FITC
(eBioscience), CD135-PE (BioLegend), CD150-PECy7 (BioLegend), CD127-PerCpCy5,5 (Bio-
Legend); Hematopoietic progenitors: Strep-APC/CY7 (Southern Biotech), cKit-APC (BD),
SCA1-PacBlue (BioLegend), CD34-FITC (eBioscience), CD16/32-PerCpCy5,5 (eBioscience),
CD127-PE (eBioscience).
RNA-seq analysis
Tissues from individual E15 embryos (brain, liver), derived cells (MEF, ESC), EμMyc lympho-
mas or human cancer cell lines (SNB19 and K562) were isolated and total RNA was extracted.
Samples were prepared using TruSeq protocol, and standard sample preparation protocols
and RNA-seq was performed on a Hiseq2000 machine (Illumina) at the NKI Genomics Core
Facility.
Bioinformatic analysis. Sequencing data were aligned to mm9 (MEFs, ESCs), mm10
(E15 brain and liver; EμMyc lymphomas), hg37 (K562 and SNB19 cells) using TopHat (v2.1.0
using bowtie 1.1.0). and number of reads per gene were measured with HTSeq count (v0.5.3).
Statistical analysis of the differential expression of genes were performed using DESeq2 [50].
Results were considered statistically significant at an adjusted p < 0.05. Normalized expression
values were obtained by correcting for differences in sequencing depth between samples using
DESeqs median-of-ratios approach. The signature gene set for Polycomb repressive complexes
(PRC1 and PRC2) and Chromodomain helicase DNA-binding (CHD) proteins were obtained
from previously published studies [51][12].
For gene set enrichment analysis using Generally Applicable Gene-set enrichment for path-
way analysis (GAGE) was used [52]. The x-axis represents enrichment score and the size of the
dots indicates the corrected p values (p.adj). An enrichment score indicates over-representa-
tion (positive) or under-representation (negative) of the DEGs in a given pathway.
Supporting information
S1 Fig. Generation of the Chd9 knockout allele by sequential targeting and Cre-mediated
deletion. (A) Representation of the targeting strategy whereby recombineering–generated cas-
settes with loxP sites were introduced sequentially by homologous recombination at the 5’ and
PLOS ONE Chromodomain helicase DNA-binding protein 9 (CHD9) is dispensable for murine development
PLOS ONE | https://doi.org/10.1371/journal.pone.0233394 May 26, 2020 15 / 22
3’ region of the Chd9 allele. Cre recombinase excision removed 5’ NEO cassette to allow subse-
quent 3’ targeting with FRT–loxP-NEO cassette, and Flp–mediated removal in-vivo. Heterozy-
gous mice were generated by breading with universal β-actin Cre recombinase strain, resulting
in the excision of the intervening 117kb genomic DNA and removal of the coding potential of
the locus (exon 3—exon 39). Southern blot hybridization in Fig 1. detects DNA fragment of
6.7kb in the wild-type, and 7.4kb in Chd9–null allele following Cre–mediated deletion. loxP
sites (red triangle), FRT sites (blue triangle), Neomycin selection cassette (grey rectangle
labelled Neo), Cre recombinase (Cre), Flp recombinase (Flp). HindIII restriction sites(red),
genomic location of the PCR probe used for Southern blot (green rectangle). (B) Integrative
Genomics Viewer (IGV) snapshot of the region surrounding the loxP site flanking exon3 (left)
and region surrounding the 3’ UTR loxP site (right). The loxP sites are 117kb apart. Active
transcription within the locus that gives rise to the 4.2kb mRNA species is represented by
RNA–seq reads from wildtype (red) and knockout (blue) MEFs.
(PDF)
S2 Fig. Immunoflourescence staining of the CHD9 protein in primary murine embryonic
fibroblasts (MEFs). Endogenous CHD9 protein is localized in distinct nuclear foci that are
absent in the knockout MEFs. Background cytoplasmic signal remains visible in the knock-
outs. Dashed white lines indicate nuclei boundaries. (Green signal CHD9, Rabbit anti-CHD9
Bethyl-labs, Alexa488), chromatin (DAPI, Blue signal). Scale bar 10μm (white line).
(PDF)
S3 Fig. Gene expression analysis of embryonic day 15 (E15) liver and brain of Chd9-/- ani-
mals. (A) Liver, (B) Brain (anticlockwise): Volcano plots represent differentially expressed
genes (DEGs) between Chd9-/- and Chd9+/+ liver (A), brain (B). The DEGs with p.adj <0.05
and log2 (fold change) > ±1 are shown, Chd9 gene is highlighted in orange. Heatmap of statis-
tically significant DEGs in Chd9-/- compared to control Chd9+/+ organs. The color scale is
based on normalized read values. Scatter-plot expression profiles of each gene in the Polycomb
repressive complex 1 (PRC1) and 2 (PRC2) and CHD family shown based on the log2 fold
change over the average expression strength. Genes highlighted in red are found to be signifi-
cant (p.adj < 0.05).
(PDF)
S4 Fig. Gene expression analysis of murine embryonic fibroblasts (MEF) and embryonic
stem cells (ESC) from Chd9-/- animals. (A) MEFs, (B) ESCs (anticlockwise): Volcano plots
represent differentially expressed genes (DEGs) between Chd9-/- and Chd9+/+ MEFs (A), ESCs
(B). The DEGs with p.adj <0.05 and log2 (fold change)> ±1 are shown, Chd9 gene is
highlighted in orange. Heatmap of statistically significant DEGs in Chd9-/- compared to con-
trol Chd9+/+ organs. The color scale is based on normalized read values. Scatter-plot expres-
sion profiles of each gene in the Polycomb repressive complex 1 (PRC1) and 2 (PRC2) and
CHD family shown based on the log2 fold change over the average expression strength. Genes
highlighted in red are found to be significant (p.adj < 0.05).
(PDF)
S5 Fig. Pseudogene Gm13237 does not affect Hmgb1 and Hmgb2 protein levels in Chd9
knockout MEFs. (A) Gm13237 is a processed pseudogene (635bp), located on mouse Chro-
mosome 4: 145,632,952–145,633,586, forward strain (mm9). It originates through genomic
integration of reverse–transcribed parental gene mRNA, and bears homology to both human
HMGB1 and HMGB2. Upper panel represents snapshot of Integrative Genome Viewer (IGV)
RNA–seq reads of Chd9 knockout (red) and wildtype (blue) MEFs. Lower panel represents
genomic location of Gm13237(ENSMUST00000122151) in the UCSC Genome Browser
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(mm9). (B) Western blot analysis (15% SDS–PAGE) of Hmgb1 and Hmgb2 proteins in Chd9
knockout and wildtype MEFs shows no difference in protein abundance and isoform expres-
sion. Gapdh is used as a loading control.
(PDF)
S6 Fig. Flow cytometric characterization of the Chd9 knockout spleen, thymus and periph-
eral blood major cell populations. (A) Flow cytometric analysis of the Chd9 wild-type (WT)
and knockout (KO) thymi: Left panel, frequency of the CD4+CD8+ double positive effector
memory T-cells and naive CD4+ and CD8+ single positive cells. Middle panel, frequency of the
immature double–negative (DN) cell subset categories, based on their expression of CD44 and
CD25 surface markers: CD44+CD25– (DNI), CD44+CD25+ (DNII), CD44–CD25+ (DN III),
and CD44–CD25– (DNIV). Right panel, total count of cells in the wild–type and knockout
thymi. Bellow, frequency of the CD4+ (left) and CD8+ T-cells (right) expressing TCR-β (T-cell
beta) receptor.(B) Flow cytometric analysis of the Chd9 WT and KO spleens: Far left panel,
frequency of the CD3+ pro-thymocytes. Left panel, frequency of the IgM/IgD double positive
naive mature B-cells. Right, frequency of the CD4 and CD8 double negative, single positive
and double positive T-cells. Absolute number of cells in spleens of Chd9 WT and KO animals.
(C) Flow cytometric analysis of the peripheral blood populations in the Chd9 WT and KO ani-
mals: Left, frequency of the lymphoid and myeloid cells, B- and T-cells (middle) and white
blood cells (eosinophils, monocytes and neutrophils). Data plotted as frequency of hematopoi-
etic cells, mean ±SD, p-value calculated using two-tailed Student’s t–test.
(PDF)
S7 Fig. Characterization of the EμMyc organs and lymphomas. (A) Autoradiogram of
Northern blot analysis of Chd9 mRNA levels in tissues derived from wildtype and EμMyc;
Chd9-/- mice using probe spanning 3’UTR. Active transcription within the knockout Chd9
locus is revealed (labelled with �). Detected mRNA from the Chd9-/- allele migrates at the size
of ~4.2kb, corresponding to the size of the remaining exons within the locus (ex1-3, ex39-40).
Chd9 has two alternatively spliced mRNA isoforms (labelled: a, b). Agarose gel shows Ethid-
ium Bromide–stained rRNA as loading control. (B) Microphotographs of a representative B-
cell lymphoma (lymphoblastic lymphoma) from the EμMyc;Chd9-/- animal, showing stainings
of hematoxylin-eosin (H&E), immunohistochemistry (IHC) of the B-cell markers B220 and
PAX5, and IHC of general T-cell marker CD3 and leukocyte marker myeloperoxidase. All
scale bars: 20mm, except for the upper right one which is 10mm. (C) Volcano plots show dif-
ferentially expressed genes (DEGs) in EμMyc;Chd9+/- (left) and EμMyc;Chd9-/- (right) com-
pared to control EμMyc;Chd9+/+ lymphomas (p.adj<0.05 and log2 (fold change) > ±1).
Upregulated genes are highlighted in red, downregulated in blue. DEGs common for EμMyc;
Chd9+/- and EμMyc;Chd9-/- samples are marked as black dots. Chd9 is highlighted in orange.
(PDF)
S8 Fig. Expression of CHD family members in different murine E15 organs, derived cells
and lymphomas and human cancer cell lines. (A, B, C, D, E) Expression profile of each gene
is based on the log2 normalized read counts for all samples. Chd9 is expressed at high levels in
all the samples analyzed. In Chd9 heterozygous and knockout samples, there is a marked
reduction in Chd9 expression. Other family members display variable levels of expression
between samples. Chd4 shows the highest expression in all the samples, whereas Chd5 is
expressed at low levels in MEFs, ESC, E15 liver, and barely detectable in lymphomas. (F, G) In
human K562 and SNB19 cancer cell lines CHD9 is expressed at high levels. Only CHD family
members with detectable expression are annotated on the Scatter-plot.
(PDF)
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S9 Fig. Chd9 is not required for proliferation or transformation of MEFs. (A) Proliferation
of MEFs assayed by crystal violet staining. Left panel shows representative example of a single
well stained with crystal violet at indicated time points. Experiment was done twice using two
Chd9 wildtype (WT) and two knockout (KO) clones seeded in triplicate. Right panel is quanti-
fication of the crystal violet staining by measuring absorbance at 590nm. Data indicates rela-
tive increase in OD590nm absorbance. Day 0 values are set as 1; data represented as
average ± standard error mean (SEM), p-value was calculated using two-way ANOVA
(ns = not significant, p-value = 0.6816). (B) Anchorage–independent growth was determined
by soft agar colony forming assay. Upper panel shows ImageJ colony number quantification of
two independent WT and KO clones. MEFs were infected with LZRS-Tbx2-GFP virus, fol-
lowed by transduction with single or combinations of indicated oncogenes (RasV12, cMyc,
E1a). Experiment using two independent WT and KO clones seeded in triplicate was repeated
twice (represented as average ± standard-error mean (SEM), p–value calculated using two-
tailed Student’s t–test) (ns = not significant). Lower panel shows representative view of the
wells containing soft–agar colonies of the transformed WT and KO MEFs used for ImageJ
quantification in the upper panel.
(PDF)
S10 Fig. CHD9 is overexpressed predominantly in cancers of neuronal and hematopoietic
origin. Gene expression data of CHD9 across panel of human cancer cell lines, taken from the
Broad Institute’s Cancer Cell Line Encyclopedia.
(PDF)
S11 Fig. CHD9 depletion deregulates gene expression in human SNB19 and K562 cancer
cells. (A) K562 chronic myelogenous leukemia and (B) SNB19 glioblastoma: (left) Unsuper-
vised hierarchical clustering of analyzed knockdown cells, each experiment was done in dupli-
cate. (Right) Volcano plots represent significant differentially expressed genes (DEGs)
between two shRNA hairpins targeting CHD9 and control hairpin targeting Luciferase. The
DEGs with FDR< 0.05 and log2 (fold change) > ±1 are shown, 20 most significant genes are
highlighted (down-blue, up-red); CHD9 gene is highlighted in orange. The DEGs are enumer-
ated at the top of each plot. (Bellow) Proliferation curve representing relative growth of knock-
down (shRNA#1 and shRNA#2 hairpins against CHD9) and control (Luciferase hairpin) cells.
Cells were treated with 1μg/ml doxycycline (DOX) two days before seeding for proliferation
assay. Doxycycline was kept throughout duration of the experiment. In case of K562, cell num-
ber was measured on cell counter, whereas for SNB19 glioblastoma relative cell growth was
determined by crystal-violet assay. Data represented as average ± standard error mean (SEM),
p-value was calculated using two-way ANOVA (for K562 cells p-value = 0.0902, for SNB19
cells p-value = 0.1977, ns = not significant). Cartoon illustrates seeding strategy.
(PDF)
S12 Fig. GAGE pathway enrichment analysis for DEGs in primary murine cells, embryonic
organs, lymphomas and human cancer cells. Each circle in the scatter plot represents a
KEGG pathway, name of the pathway is denoted on the Y-axis and the enrichment score the
X-axis. The size of the dots corresponds to the -log10(padj) value, indicating statistically signif-
icant KEGG categories. An enrichment score indicates over-representation (positive) or
under-representation (negative) of the DEGs in a given pathway. KEGG categories mentioned
in the main text are highlighted in red (over-represented), blue (under-represented).
(PDF)
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S13 Fig. Uncropped images of Western blots. The number of the corresponding Figure in





We thank Rahmen Bin Ali for technical assistance in generating the mice. We thank members
of the Animal facility of the Netherlands Cancer Institute for maintaining the mice. We thank
members of the Department of Experimental Animal Pathology and members of the Geno-
mics Core Facility of the Netherlands Cancer Institute. Authors would like to thank Dr. Maar-
ten van Lohuizen (The Netherlands Cancer Institute, Amsterdam) for critically reading the
manuscript.
Author Contributions
Conceptualization: Andrej Alendar, Anton Berns.
Data curation: Andrej Alendar, Anton Berns.
Formal analysis: Andrej Alendar, Jan-Paul Lambooij, Rajith Bhaskaran, Cesare Lancini, Ji-
Ying Song, Margriet Snoek.
Funding acquisition: Anton Berns.
Investigation: Andrej Alendar, Jan-Paul Lambooij.




Supervision: Andrej Alendar, Margriet Snoek, Anton Berns.
Visualization: Andrej Alendar, Rajith Bhaskaran, Cesare Lancini, Ji-Ying Song.
Writing – original draft: Andrej Alendar, Margriet Snoek, Anton Berns.
Writing – review & editing: Andrej Alendar, Anton Berns.
References
1. Narlikar GJ, Sundaramoorthy R, Owen-Hughes T. Mechanisms and Functions of ATP-Dependent
Chromatin-Remodeling Enzymes. Cell. 2013 Aug; 154(3):490–503. https://doi.org/10.1016/j.cell.2013.
07.011 PMID: 23911317
2. Murawska M, Brehm A. CHD chromatin remodelers and the transcription cycle. Biochem Soc Symp.
2011 Nov; 2(6):244–53.
3. Ryan DP, Sundaramoorthy R, Martin D, Singh V, Owen-Hughes T. The DNA-binding domain of the
Chd1 chromatin-remodelling enzyme contains SANT and SLIDE domains. Embo J. 2011 Jul 6; 30
(13):2596–609. PMID: 21623345
4. Ishihara K, Oshimura M, Nakao M. CTCF-dependent chromatin insulator is linked to epigenetic remodel-
ing. Mol Cell. 2006 Sep 1; 23(5):733–42. https://doi.org/10.1016/j.molcel.2006.08.008 PMID: 16949368
5. Kennison JA, Tamkun JW. Dosage-dependent modifiers of polycomb and antennapedia mutations in
Drosophila. Proc National Acad Sci. 1988; 85(21):8136–40.
PLOS ONE Chromodomain helicase DNA-binding protein 9 (CHD9) is dispensable for murine development
PLOS ONE | https://doi.org/10.1371/journal.pone.0233394 May 26, 2020 19 / 22
6. Srinivasan S, Dorighi KM, Tamkun JW. Drosophila Kismet Regulates Histone H3 Lysine 27 Methylation
and Early Elongation by RNA Polymerase II. Plos Genet. 2008 Oct; 4(10):e1000217. https://doi.org/10.
1371/journal.pgen.1000217 PMID: 18846226
7. Terriente-Fe´lix A, Molnar C, Go´mez-Skarmeta JL, de Celis JF. A conserved function of the chromatin
ATPase Kismet in the regulation of hedgehog expression. Dev Biol. 2011 Feb 15; 350(2):382–92.
https://doi.org/10.1016/j.ydbio.2010.12.003 PMID: 21146514
8. Daubresse G, Deuring R, Moore L, Papoulas O, Zakrajsek I, Waldrip WR, et al. The Drosophila kismet
gene is related to chromatin-remodeling factors and is required for both segmentation and segment
identity. Dev Camb Engl. 1999; 126(6):1175–87.
9. Kent RS, Marom R, John S, Dundr M, Schiltz LR, Gutierrez J, et al. New face for Chromatin-Related
Mesenchymal Modulator: n-CHD9 localizes to nucleoli and interacts with ribosomal genes. J Cell Phy-
siol. 2015 Feb 16; 230(9):2270–80. https://doi.org/10.1002/jcp.24960 PMID: 25689118
10. Manning BJ, Yusufzai T. The ATP-dependent Chromatin Remodeling Enzymes CHD6, CHD7, and
CHD8 Exhibit Distinct Nucleosome Binding and Remodeling Activities. J Biol Chem. 2017 May 21; 292
(28):jbc.M117.779470.
11. Rodriguez-Paredes M, Ceballos-Chavez M, Esteller M, Garcia-Dominguez M, Reyes JC. The chroma-
tin remodeling factor CHD8 interacts with elongating RNA polymerase II and controls expression of the
cyclin E2 gene. Nucleic Acids Res. 2009 May 6; 37(8):2449–60. https://doi.org/10.1093/nar/gkp101
PMID: 19255092
12. Gaspar-Maia A, Alajem A, Meshorer E, Ramalho-Santos M. Open chromatin in pluripotency and repro-
gramming. Nat Rev Mol Cell Bio. 2011 Jan; 12(1):36–47.
13. Hurd EA, Capers PL, Blauwkamp MN, Adams ME, Raphael Y, Poucher HK, et al. Loss of Chd7 function
in gene-trapped reporter mice is embryonic lethal and associated with severe defects in multiple devel-
oping tissues. Mamm Genome. 2007 Feb; 18(2):94–104. https://doi.org/10.1007/s00335-006-0107-6
PMID: 17334657
14. Nishiyama M, Oshikawa K, Tsukada Y, Nakagawa T, Iemura S, Natsume T, et al. CHD8 suppresses
p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. Nat Cell Biol.
2009 Jan 18; 11(2):172–82. https://doi.org/10.1038/ncb1831 PMID: 19151705
15. Bosman EA, Penn AC, Ambrose JC, Kettleborough R, Stemple DL, Steel KP. Multiple mutations in
mouse Chd7 provide models for CHARGE syndrome. Hum Mol Genet. 2005 Nov 15; 14(22):3463–76.
https://doi.org/10.1093/hmg/ddi375 PMID: 16207732
16. Katayama Y, Nishiyama M, Shoji H, Ohkawa Y, Kawamura A, Sato T, et al. CHD8 haploinsufficiency
results in autistic-like phenotypes in mice. Nature. 2016 Sep 7; 537(7622):675–9. https://doi.org/10.
1038/nature19357 PMID: 27602517
17. Chu X, Guo X, Jiang Y, Yu H, Liu L, Shan W, et al. Genotranscriptomic meta-analysis of the CHD family
chromatin remodelers in human cancers—initial evidence of an oncogenic role for CHD7. Molecular
oncology. 2017 Oct; 11(10):1348–60. https://doi.org/10.1002/1878-0261.12104 PMID: 28649742
18. Kim MS, Chung NG, Kang MR, Yoo NJ, Lee SH. Genetic and expressional alterations of CHD genes in
gastric and colorectal cancers. Histopathology. 2011 Apr; 58(5):660–8. https://doi.org/10.1111/j.1365-
2559.2011.03819.x PMID: 21447119
19. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. Frequent mutations of chromatin remodeling genes
in transitional cell carcinoma of the bladder. Nat Genet. 2011 Sep; 43(9):875–8. https://doi.org/10.1038/
ng.907 PMID: 21822268
20. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct sub-
groups of medulloblastoma. Nature. 2012 Aug 2; 488(7409):43–8. https://doi.org/10.1038/nature11213
PMID: 22722829
21. Badodi S, Dubuc A, Zhang X, Rosser G, Jaeger MDC, Kameda-Smith MM, et al. Convergence of BMI1
and CHD7 on ERK Signaling in Medulloblastoma. Cell Reports. 2017 Dec 5; 21(10):2772–84. https://
doi.org/10.1016/j.celrep.2017.11.021 PMID: 29212025
22. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and sat-
uration analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23; 505(7484):495–501.
https://doi.org/10.1038/nature12912 PMID: 24390350
23. Surapureddi S, Viswakarma N, Yu S, Guo D, Rao MS, Reddy JK. PRIC320, a transcription coactivator,
isolated from peroxisome proliferator-binding protein complex. Biochemical and Biophysical Research
Communications. 2006 May; 343(2):535–43. https://doi.org/10.1016/j.bbrc.2006.02.160 PMID:
16554032
24. Shur I, Benayahu D. Characterization and functional analysis of CReMM, a novel chromodomain heli-
case DNA-binding protein. J Mol Biol. 2005 Sep 23; 352(3):646–55. https://doi.org/10.1016/j.jmb.2005.
06.049 PMID: 16095617
PLOS ONE Chromodomain helicase DNA-binding protein 9 (CHD9) is dispensable for murine development
PLOS ONE | https://doi.org/10.1371/journal.pone.0233394 May 26, 2020 20 / 22
25. Lee BH, Stallcup MR. Glucocorticoid Receptor Binding to Chromatin is Selectively Controlled by Core-
gulator Hic-5 and Chromatin Remodeling Enzymes. J Biol Chem. 2017 Apr 5; 292(22):jbc.M117.78707.
26. Ooga M, Funaya S, Hashioka Y, Fujii W, Naito K, Suzuki MG, et al. Chd9 mediates highly loosened
chromatin structure in growing mouse oocytes. Biochem Bioph Res Co. 2018 Jun 7; 500(3):583–8.
27. de Dieuleveult M, Yen K, Hmitou I, Depaux A, Boussouar F, Dargham DB, et al. Genome-wide nucleo-
some specificity and function of chromatin remodellers in ES cells. Nature. 2016 Jan 27; 530
(7588):113–6. https://doi.org/10.1038/nature16505 PMID: 26814966
28. Orkin SH, Wang J, Kim J, Chu J, Rao S, Theunissen TW, et al. The transcriptional network controlling
pluripotency in ES cells. Cold Spring Harb Sym. 2008; 73(0):195–202.
29. Shur I, Socher R, Benayahu D. In vivo association of CReMM/CHD9 with promoters in osteogenic cells.
J Cell Physiol. 2006 May; 207(2):374–8. https://doi.org/10.1002/jcp.20586 PMID: 16419031
30. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, et al. High-throughput retroviral tagging to
identify components of specific signaling pathways in cancer. Nat Genet. 2002 Sep; 32(1):153–9.
https://doi.org/10.1038/ng950 PMID: 12185366
31. Berquam-Vrieze KE, Nannapaneni K, Brett BT, Holmfeldt L, Ma J, Zagorodna O, et al. Cell of origin
strongly influences genetic selection in a mouse model of T-ALL. Blood. 2011 Oct 27; 118(17):4646–56.
https://doi.org/10.1182/blood-2011-03-343947 PMID: 21828136
32. Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of
XSCID gene therapy. Proc National Acad Sci. 2006 Aug 1; 103(31):11730–5.
33. Guzman-Ayala M, Sachs M, Koh FM, Onodera C, Bulut-Karslioglu A, Lin C-J, et al. Chd1 is essential for
the high transcriptional output and rapid growth of the mouse epiblast. Development. 2015 Jan 1; 142
(1):118–27. https://doi.org/10.1242/dev.114843 PMID: 25480920
34. O’Shaughnessy-Kirwan A, Signolet J, Costello I, Gharbi S, Hendrich B. Constraint of gene expression
by the chromatin remodelling protein CHD4 facilitates lineage specification. Development. 2015 Aug 1;
142(15):2586–97. https://doi.org/10.1242/dev.125450 PMID: 26116663
35. Li W, Wu J, Kim S-Y, Zhao M, Hearn SA, Zhang MQ, et al. Chd5 orchestrates chromatin remodelling
during sperm development. Nature communications. 2014; 5:3812. https://doi.org/10.1038/
ncomms4812 PMID: 24818823
36. Coulthard LG, Hawksworth OA, Woodruff TM. Complement: The Emerging Architect of the Developing
Brain. Trends in neurosciences. 2018 Jun; 41(6):373–84. https://doi.org/10.1016/j.tins.2018.03.009
PMID: 29606485
37. Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nature
Reviews Genetics. 2016 May; 17(5):272–83. https://doi.org/10.1038/nrg.2016.20 PMID: 27040487
38. Huang H-T, Kathrein KL, Barton A, Gitlin Z, Huang Y-H, Ward TP, et al. A network of epigenetic regula-
tors guides developmental haematopoiesis in vivo. Nature Cell Biology. 2013 Dec; 15(12):1516–25.
https://doi.org/10.1038/ncb2870 PMID: 24240475
39. Shingleton JR, Hemann MT. The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell
Survival in Murine Hematopoietic Malignancies. PLoS ONE. 2015; 10(11):e0143275. https://doi.org/10.
1371/journal.pone.0143275 PMID: 26588464
40. Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche. Nature Reviews
Molecular Cell Biology. 2019 Apr 17; 20(5):1–18.
41. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of mye-
loma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010 Oct
14; 116(15):e56–65. https://doi.org/10.1182/blood-2010-04-279596 PMID: 20616218
42. Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, et al. Global microRNA expression profiling uncovers
molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 2015 Feb 12;
125(7):1137–45. https://doi.org/10.1182/blood-2014-04-566778 PMID: 25498913
43. Jager PLD, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, et al. Alzheimer’s disease: early
alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nature neuroscience.
2014 Sep; 17(9):1156–63. https://doi.org/10.1038/nn.3786 PMID: 25129075
44. Behan FM, Iorio F, Picco G, Gonc¸alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer thera-
peutic targets using CRISPR-Cas9 screens. Nature. 2019 Apr 10; 568(7753):1–516.
45. Liu P, Jenkins NA, Copeland NG. A highly efficient recombineering-based method for generating condi-
tional knockout mutations. Genome Research. 2003 Mar; 13(3):476–84. https://doi.org/10.1101/gr.
749203 PMID: 12618378
46. Osoegawa K, Tateno M, Woon PY, Frengen E, Mammoser AG, Catanese JJ, et al. Bacterial artificial
chromosome libraries for mouse sequencing and functional analysis. Genome Res. 2000; 10(1):116–
28. PMID: 10645956
PLOS ONE Chromodomain helicase DNA-binding protein 9 (CHD9) is dispensable for murine development
PLOS ONE | https://doi.org/10.1371/journal.pone.0233394 May 26, 2020 21 / 22
47. Harris AW. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and
leukemia of early B cells. The Journal of experimental medicine. 1988 Feb 1; 167(2):353–71. https://doi.
org/10.1084/jem.167.2.353 PMID: 3258007
48. Huijbers IJ, Bravo JD, Ali RB, Pritchard C, Braumuller TM, van Miltenburg MH, et al. Using the GEMM-
ESC strategy to study gene function in mouse models. Nature Protocols. 2015 Oct 15; 10(11):1755–85.
https://doi.org/10.1038/nprot.2015.114 PMID: 26492136
49. Lancini C, van den Berk PCM, Vissers JHA, Gargiulo G, Song J-Y, Hulsman D, et al. Tight regulation of
ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic
stem cells. The Journal of experimental medicine. 2014 Aug 25; 211(9):1759–77. https://doi.org/10.
1084/jem.20131436 PMID: 25113974
50. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data
with DESeq2. Genome biology. 2014 Dec 5; 15(12):31–21.
51. Croce LD, Helin K. Transcriptional regulation by Polycomb group proteins. Nature Structural & Molecu-
lar Biology. 2013 Oct 1; 20(10):1147–55.
52. Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ. GAGE: generally applicable gene set
enrichment for pathway analysis. BMC bioinformatics. 2009; 10(1):161–17.
PLOS ONE Chromodomain helicase DNA-binding protein 9 (CHD9) is dispensable for murine development
PLOS ONE | https://doi.org/10.1371/journal.pone.0233394 May 26, 2020 22 / 22
